---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-012408"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2022-09-13T23:59:59+00:00"
generated_at: "2026-06-23T10:31:17.980444+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI Phase 3 Multikine at ESMO: 45 responses, all in treatment group (1 in 100B chance), >3x OS benefit

## Summary
- 45 RECIST neoadjuvant responses including 5 complete; all exclusive to Multikine groups (1 in 100 billion chance).
- Overall survival >3x longer for responders vs non-responders.
- Early tumor response (pre-surgery) noted only in Multikine groups, not control; prognostic and predictive for OS.
- Biomarker analysis: low tumor PDL1, high immune cell density, specific ratios predict Multikine efficacy.
- Data from the largest Phase 3 study ever in newly diagnosed locally advanced head and neck cancer.

## SEC filing metadata
- accession: 0001654954-22-012408
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2022-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/0001654954-22-012408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-012408
- JSON: https://secwatch.observer/filing/0001654954-22-012408.json
- Plain text: https://secwatch.observer/filing/0001654954-22-012408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.